Introduction
Major depressive disorder (MDD) is a severe mental disorder characterized by sustained negative mood [1], a persistent lack of motivation, and difficulty experiencing pleasure that substantially affects patients’ quality of daily life [2]. Overall, 78% of patients with severe depression were diagnosed with at least one comorbid psychiatric disorder, such as psychotic disorder, past panic disorder, anxiety, and even suicide risk [3], [4]. MDD is not a homogeneous disorder but a complex disease with a variety of etiologies. Many studies have also shown dysfunctions in the areas of the brain modulated by corresponding systems, including the frontal cortex, amygdala, hippocampus, and basal ganglia, in depression patients. These specific brain regions are highly vulnerable to the effects of stress, probably accounting for the adverse effects of life events on MDD [5]. The severity of MDD is indexed by a composite of several behavioral measures or aspects of depressive perception. Therefore, clinicians score the degree of depressive symptoms using the 17-item clinician-administered Hamilton Depression Rating Scale (HAMD17), which classifies patients with MDD into 4 grades on a 54-point scale using a 17-item questionnaire ranging from normal (0-7 points), mild depression (8-16 points), and moderate depression (17-23 points) to severe depression (> 24 points) [6].
Multiple therapies have been proposed and verified to be available and effective for MDD, among which psychotherapy and medications have been widely used [7]. For patients suffering from dysthymia, medication is more effective than psychotherapy, whereas blended treatment does not result in greater efficacy than either medication or psychotherapy [8]. Sertraline and escitalopram are often considered the first-line medicines for the treatment of depression [9]. Although different antidepressants display similar efficacy on average [10], the treatment selection is not effective for all patients with MDD [11]. Since the efficacy of different medicines is highly divergent, patients who exhibit a poor response to one treatment, up to one-half, attain a benefit after changing to another medicine [12]. Unfortunately, more than half of patients do not complete follow-up visits, leading them to fail to receive additional medication options [13]. Even for patients who return to pursue further treatment and finally benefit from second-line medicines, failing to obtain effective therapy at the initial stage of treatment substantially extends their treatment period (the time lag is up to 6 weeks), imposing a substantial burden on them [14]. Therefore, accurately matching patients with the best initial treatment might provide tremendous advantages to people suffering from MDD.
Recently, researchers have tried to identify biomarkers that will inform the choice of specific medications [8], [15]. For example, Wu and colleagues designed a latent-space machine-learning algorithm that utilized band power as the feature to predict symptom improvement in a manner specific to the antidepressant sertraline [16]. This approach, however, is unable to show the overall relationship among related brain regions. Band power did not work effectively in distinguishing non-responders from responders at baseline. In essence, in addition to the local band power, the global interregional couplings in the brain measured using electroencephalogram (EEG) have been reported to be a more objective measure for quantitatively evaluating therapeutic efficacy [17], [18]. In fact, analyzing the inherent information recorded by EEG provides the opportunity to investigate the network architecture of the brain, revealing the information propagation and exchange among different regions [19], [20], [21], [22]. Specifically, the corresponding information is usually processed among those spatially distributed but functionally interacting brain areas [22], [23], [24], which maps the spatial topological architecture that illustrates the neurophysiological pathogenicity of MDD [2], [25]. As reported previously, Shim and colleagues obtained a broader view of the brain with longer path length and decreased clustering coefficient in alpha and theta bands, which illustrated the deficient connectivity in patients with depression [26]. In another study, Li and colleagues reported abnormally increased synchronization consisting of denser short-range frontal and temporal-parietal connections for an n-back task, explaining the compensatory mechanism for memory impairment in patients with depression [27].
Furthermore, investigators have recently utilized related brain networks to distinguish the differences between patients with MDD and healthy controls, assisting in providing a better understanding of the mechanism underlying depression [28], [29]. For example, in a previous study conducted by Mohammadi and Moradi, the potential relationship between the regional activity in patients with MDD and their depression severity was not only identified but also provided a quantitative depression severity prediction [30]. Gamma wave coherence has also been found to help discriminate patients with mild depression from healthy controls, as they manifested lower gamma coherence than healthy controls [31]. However, studies of the treatment response, especially short-term treatment response, thus far, are not yet sufficient and still await further investigation by performing EEG network analyses. Consequently, the identification of robust predictors provides significant benefits in terms of understanding and predicting that variation [15].
In the present study, the data we utilized were downloaded from a public data archive, the National Institute of Mental Health Data Archive (NDA). The data are publicly available through the official website (https://nda.nih.gov/edit_collection.html?id=2199). Recently, multiple studies have been conducted using these datasets. For example, Zhang and colleagues identified clinically relevant MDD subtypes using (un)supervised machine learning based on distinct network patterns [1]. Yu and colleagues investigated network differences within and between resting-state networks in patients with MDD and healthy controls and found that traumatic childhood experiences and dimensional symptoms are linked to abnormal network architecture in these patients with MDD [32]. Although these studies have been implemented, the treatment response, especially short-term treatment response, has not yet been studied extensively and is still awaiting further investigation by performing EEG network analyses. Therefore, in our present study, we analyzed the resting-state EEG datasets from patients with MDD collected before and after their one-week antidepressant medication therapy. Related brain networks of these patients with MDD were constructed and then statistically compared to explore the brain fluctuations after one-week medication, as well as predict its eight-week efficacy.
Materials And Methods
A. EEG Data
The EEG data were selected from the study “Establishing Moderators and Biosignatures of Antidepressant Response in Clinic Care (EMBARC)” in the National Institute of Mental Health Data Archive (NDA). In this study, patients were recruited from different centers. However, in addition to Columbia University, data from fewer qualified subjects were obtained from the other centers due to the poor quality of EEG data and failure of follow-up visits in the later stage of medication therapy. Therefore, only the EEG data from 30 patients treated at Columbia University were included in our current study. The 30 participants with MDD participated in a randomized trial and received sertraline, and their clinical and biological markers of outcomes were evaluated [33]. In detail, the 30 subjects were assigned to an 8-week treatment of sertraline of up to 200 mg daily. Sertraline dose adjustments occurred at weeks 1, 2, 3, 4, 6, and 8 to ensure delivery of the appropriate dose and to record the symptom reduction (measured by HAMD17). The raw data for each patient included two 2-min blocks of eyes-opened resting EEG. The EEG datasets were collected at Columbia University/Stony Brook (Data Center) in the United States at baseline (0 W) and one week after the treatment (1 W) using a high-density EEG system (BioSemi, 72 channels). During online data recording, patients were seated in a quiet and electrically shielded room with their eyes open and relaxed as much as possible, and electrodes PPO1 and PPO2 served as the reference. EEG signals were sampled at 256 Hz and online bandpass filtered at 0-251.3 Hz. At week 8, the 30 patients were assessed with the Clinical Global Improvement scale (CGI), and subjects who received a CGI score worse than “much improved” (i.e., having a CGI score greater than 2) were deemed non-responders, while the remaining patients who scored “much improved” or “very much improved” (i.e., having a CGI score of 1 or 2) were considered responders.
B. Methods
In this study, resting-state EEG datasets were used to construct the corresponding brain networks with MATLAB v2014a software (The MathWorks Inc.). The data analysis procedure is presented in Fig. 1. Detailed descriptions of data processing are provided in the subsequent sections.
Procedures used to analyze resting-state EEG datasets. (a) Preprocessing of the resting-state EEG datasets, (b) Prediction of the treatment outcome based on resting-state EEG networks, and (c) Discrimination of responders and non-responders based on resting-state EEG networks.
1) EEG Preprocessing:
In the present study, we mainly focused on investigating the potential capacity of the resting-state brain network to quantitatively evaluate the brain fluctuations after short-term medication and distinguish responders from non-responders. Therefore, concerning these resting-state EEG datasets, before preprocessing, the first and last ten seconds of EEG signals were first excluded, and multiple preprocessing procedures were then applied to complete data preprocessing, which included averaging-referencing, [1], [42] Hz bandpass filtering, and 5-s-length data segmentation. Thereafter, a threshold of ±
2) Functional Brain Networks:
As proven in previous studies, brain network analysis is remarkably helpful in explaining the neurophysiological pathogenicity of MDD [2], and a related analysis was thus implemented in our study. Actually, an EEG network has been typically modeled as a collection of nodes (i.e., EEG electrodes) and edges that are evaluated between paired electrodes [34], [35]. When constructing the corresponding EEG network for all patients with MDD, the same definition of the EEG network is considered. Specifically, we set 21 electrodes as the network nodes, and after extracting the EEG signal for each electrode, the estimated paired-electrode interactions were then regarded as the network edges. Here, when constructing resting-state networks for patients with MDD, the synchronization likelihood between pairwise electrodes was considered [36], [37]. As suggested in previous studies, the phase locking value (PLV) [38], [39] that experts in estimating the phase synchronization among pairwise signals was thus adopted, leading to an adjacency matrix with the dimension of electrodes
As formulated, the Hilbert transform (HT) is used to form the analytical signal \begin{align*} \begin{cases} \displaystyle {H_{x} (t)=x(t)+iHT_{x} (t)} \\ \displaystyle {\textrm {H}_{y} (t)=y(t)+iHT_{y} (t)} \end{cases}\tag{1}\end{align*}
\begin{align*} \begin{cases} \displaystyle {HT_{x} (t)=\frac {1}{\pi }P.V.\int _{-\infty }^{\infty} {\frac {x({t}')}{t-{t}'}} d{t}'} \\ \displaystyle {HT_{y} (t)=\frac {1}{\pi }P.V.\int _{-\infty }^{\infty} {\frac {y({t}')}{t-{t}'}} d{t}'} \end{cases}\tag{2}\end{align*}
\begin{align*} \begin{cases} \displaystyle {\varphi _{\textrm {x}} (t)=\arctan \frac {HT_{x} (t)}{x(t)}} \\ \displaystyle {\varphi _{\textrm {y}} (t)=\arctan \frac {HT_{y} (t)}{y(t)}} \end{cases}\tag{3}\end{align*}
Finally, the PLV was formulated as follows:\begin{equation*} \textrm {w}^{plv}=\left \vert{ {\frac {1}{N}\sum \limits _{j=0}^{N-1} {e^{\textrm {i}(\varphi _{x} (j\Delta t)-\varphi _{y} (j\Delta t)})}} }\right \vert\tag{4}\end{equation*}
Concretely, based on those artifact-free resting-state EEG segments from each patient, the PLV was first applied to each segment to acquire the corresponding
Furthermore, two weighted network properties were calculated using these constructed EEG networks, the clustering coefficient (\begin{align*} {C}=&\frac {1}{n}\sum \limits _{i\in \Psi } {\frac {\sum \limits _{j,h\in \Psi } {\left ({{w_{ij}^{plv} w_{ih}^{plv} w_{jh}^{plv}} }\right)}^{1 \mathord {\left /{ {\vphantom {1 3}} }\right. } 3}}{\sum \limits _{j\in \Psi } {w_{ij}^{plv} \left ({{\sum \limits _{j\in \Psi } {w_{ij}^{plv}} -1} }\right)}}} \tag{5}\\ {L}=&\frac {1}{n}\sum \limits _{i\in \Psi } {\frac {\sum \limits _{j\in \Psi,j\ne i} {d_{i}}_{j}}{n-1}}\tag{6}\end{align*}
Afterward, we statistically analyzed the potential differences in these weighted network properties between responders and non-responders using an independent
3) The Prediction of Medication Efficacy Using a Multiple Linear Regression Model:
In the present study, the changes in the two resting-state network properties (i.e., \begin{equation*} \textrm {Y}=\beta _{0} +\beta _{1} \Delta \textrm {C}+\beta _{2} \Delta \textrm {L}+\varepsilon\tag{7}\end{equation*}
Here, the leave-one-out cross-validation (LOOCV) strategy was used to predict the eight-week medication efficacy in all patients with MDD [40]. Specifically, for
4) Discrimination of Responders From Non-Responders Based on Resting-State Networks:
Eventually, these resting-state networks were further tested to prove whether they also promote the clinical selection of optimal therapeutic strategies for MDD, which were validated using two different types of network features. First, these resting-state network properties were adopted. In detail, all of these patients with MDD were divided into training and testing subgroups. During the training process, the corresponding training weighted network properties (i.e.,
As proven previously, these network properties are direct statistical measurements of brain networks. Although they might also quantitatively capture the overall network differences under our conditions of interest, the corresponding spatial network information is still unmined [41]. Thus, the network property can be used to describe the overall brain network but does not encompass all features contained in the network topology. In our previous studies, we developed the spatial pattern of the network (SPN) [42] to extract the discriminative spatial pattern contained in a given brain network [42]. As the SPN was described in detail in our previous studies [42], a brief introduction to this method was primarily provided here.
\begin{equation*} {J}(z)=\frac {zM_{1} M_{1}^{T} z^{T}}{zM_{2} M_{2}^{T} z^{T}}=\frac {z{\mathrm{ A}}_{1} z^{T}}{z{\mathrm{ A}}_{2} z^{T}}\tag{8}\end{equation*}
Because the scaling of projection z will have no effect on the object value, Eq. (8) can be rewritten as the following constrained optimization problem:\begin{align*} \begin{cases} \displaystyle \mathop {arg\,\textrm {max}}\limits _{z} & z{\mathrm{ A}}_{1} \textrm {z}^{\textrm {T}} \\ \displaystyle subject to & z{\mathrm{ A}}_{2} \textrm {z}^{\textrm {T}} =1 \end{cases}\tag{9}\end{align*}
By introducing the Lagrange multiplier, Eq. (9) can be further rewritten as follows:\begin{equation*} \textrm {L}\,(z,\lambda)=z{\mathrm{ A}}_{1} z^{T}-\lambda (z{\mathrm{ A}}_{2} z^{T}-1)\tag{10}\end{equation*}
Then, the objective projection z is estimated utilizing the generalized eigenvalue equation by taking the derivative of Eq. (10) with respect to z under the condition \begin{equation*} {\mathrm{ A}}_{1} \textrm {z}^{\textrm {T}}=\lambda {\mathrm{ A}}_{2} z^{T}\tag{11}\end{equation*}
For multiple \begin{equation*} {\mathrm{ A}}_{2}^{-1} {\mathrm{ A}}_{1} Z^{T}=\sum {Z^{T}}\tag{12}\end{equation*}
Additionally, given the adjacency matrices of the depression patients, the corresponding SPN features (\begin{align*} F_{SPN}=&log(var(V_{SPN}^{T} M)) \\ with V_{SPN}=&[z_{1},z_{2},\ldots,z_{i}]\tag{13}\end{align*}
As clarified in previous studies, the increasing pairs of SPN filters might facilitate the classification of situations of interest [41], [42]; for example, different pairs of SPN features (i.e., 1 pair, 2 pairs, and 3 pairs) have been used to achieve the classification of psychogenic nonepileptic seizures from epilepsy, and 3 pairs of SPN features achieved the highest classification accuracy [42]. Consistent with the protocols used in previous studies [43], [44], in our present study, three pairs of SPN filters were accordingly adopted to achieve the classification of responders and non-responders. In particular, for a
When using the SPN features to classify the responders and non-responders, protocols similar to those used to analyze network properties were performed. Specifically, after acquiring the trained SPN filters during the training process, we subsequently calculated the corresponding training SPN features (Eq. (13)) that would be used to train the LDA classifier. Additionally, the trained filters were further applied to the testing sets to acquire the testing SPN features. Eventually, the testing SPN features were input into the trained LDA classifier, and the related classification performance was evaluated accordingly.
As the present dataset was relatively small, the LOOCV test was also used to recognize responders and non-responders, as described in previous studies [45], [46]. Based on the LOOCV, the corresponding indices, including accuracy (ACC), sensitivity (SEN), and specificity (SPE), were then calculated to evaluate the performance. Let \begin{align*} {A}CC=&\frac {n_{Res} +n_{Non}}{N_{Res} +N_{Non} }\times 100\% \tag{14}\\ SEN_{Res}=&\frac {n_{Res}}{N_{Res}}\times 100\% \tag{15}\\ SPE_{Non}=&\frac {n_{Non}}{N_{Non}}\times 100\%\tag{16}\end{align*}
Results
A. Comparison of HAMD17 Scores Between Responders and Non-Responders at Baseline and After One Week of Medication
Medication treatment visits occurred at baseline and weeks 1, 2, 3, 4, 6, and 8 to ensure that the delivery was appropriate and to record the HAMD17score. Although these scales have some defects, they are still currently crucial for the clinical diagnosis of related diseases, and the classification in the neuroscience field also uses clinical scales as the evaluation criteria [47], [48]. Therefore, using the same protocol described in previous studies [49], [50], these clinical scores of all patients were also recorded as the “gold standard” when evaluating and classifying the patients. Concretely, considering the EEG datasets used in this study and methods reported in previous studies [51], [52], 30 patients were assessed with the CGI at the 8th week. In addition, expanding on the CGI criteria, 9 patients who received a score worse than “much improved” were deemed to be medication non-responders, while the remaining 21 patients who scored “much improved” or “very much improved” were then considered responders [33]. The 0 W minus 1 W fluctuations in HAMD17 scores were primarily calculated to quantify the efficacy of the antidepressant medication; unfortunately, as displayed in Fig. 2(a), no statistically significant differences were identified in HAMD17 score fluctuations for both patient groups. Because resting-state EEG datasets were only collected at two stages, i.e., at baseline and week 1, the efficacy within the relatively short medication duration (i.e., only baseline and week 1) was also considered. Concretely, the corresponding differences in HAMD17 scores between the responders and non-responders were statistically analyzed at both baseline and week 1. Not surprisingly, no significant differences in HAMD17 scores were observed between the two groups at either stage (
Statistical differences in HAMD17 scores between non-responders and responders. (a) HAMD17 score fluctuations after one week of antidepressant medication. (b) HAMD17 scores at baseline and week 1.
B. Brain Fluctuations After Short-Term Medication Indexed by Resting-State EEG Networks
1) Network Differences Between 0 W and 1 W:
Next, we sought to identify a robust biomarker that quantitatively evaluated patients’ brain fluctuations after one-week antidepressant treatment, which might help predict the final medication efficacy in patients with MDD. Here, expanding upon the constructed resting-state EEG networks for all patients, the corresponding implicit spatial network topologies and related network properties, were first statistically compared to validate the sensitivity of network measures to antidepressant treatment.
On the one hand, we concentrated on the corresponding network topologies measured for responders in both stages. Fig. 3(a) shows the significant differences in network topologies between baseline (i.e., 0 W) and one week of medication (i.e., 1 W), in which the red solid lines denote the reduced interelectrode connectivity (0 W > 1 W). Specifically, relatively stronger connectivity (i.e., red long-range edges) among the frontal and occipital lobes was observed at the baseline stage (
The significant differences in network topology and properties in responders between 0 W and 1 W. (a) Network topology. (b) Network properties.
2) Prediction of the Medication Efficacy Based on Resting-State Network Properties:
Because these resting-state network characteristics (both topologies and properties) were identified to help evaluate the brain fluctuations after one-week medication therapy, we then intended to explore whether any potential relationship between the HAMD17 score fluctuations and the corresponding network property changes (
Relationships between changes in the network properties and changes in the HAMD17 score during one week of medication. In each subfigure, the red line is the fitted curve, and the blue filled circles denote the patients with MDD.
In addition to the potential relationship between network property changes and changes in the HAMD17 score at one week, related network properties were analyzed to clarify whether they might also facilitate the prediction of treatment outcomes; in particular, we predicted the treatment efficacy after eight weeks of medication. Here, the eventual treatment efficacy was quantified as the difference in HAMD17 scores at baseline from the 8th week, and the differences in network properties between the baseline and one-week medication were used as the corresponding predicting features. By implementing the linear prediction analysis, we then predicted the changes in the HAMD17 score for all patients with MDD. Consequently, as displayed in Fig. 5, the predicted changes in HAMD17 scores were significantly related to the actual changes. The corresponding Pearson’s correlation coefficient was
Prediction of eight-week medication efficacy (changes in the HAMD17 scores) based on the resting-state network properties. The black dashed line indicates the ideal prediction, the red line fits the scatter points, and the blue filled circles denote the subjects.
C. Medication Sensitivity of Patients With MDD Derived From Resting-State Networks
1) Network Differences Between Responders and Non-Responders:
The differences in resting-state EEG networks between responders and non-responders were also investigated at the baseline and one-week medication stages to further validate the great potential of network characteristics in determining the response of medication therapy in patients with MDD. Fig. 6(a) and (b) illustrate the significant differences in network topology and properties between the two groups. Concretely, Fig. 6(a) displays the topological difference at baseline, in which weaker linkages are identified for the responders than for the non-responders. In addition, the corresponding differences (
The significant differences in network topology and properties between responders and non-responders at 0 W and 1 W: (a) 0 W and (b) 1 W.
2) Categorization Into Responders and Non-Responders Based on Resting-State Networks:
Based on the statistically significant difference in network properties between responders and non-responders at the baseline stage shown in Fig. 6(a), we next examined whether the corresponding network properties also discriminated non-responders from responders before the actual treatment, which might facilitate the precise treatment of MDD in the clinic if this medication therapy was effective in these patients with MDD. These results might guide the design of a more effective treatment protocol. In fact, although significant differences in network properties were identified between both groups, the 76.67% classification accuracy acquired here was not as satisfying as expected, as well as the sensitivity of 76.19% for responders and the specificity of 77.78% for non-responders.
In addition to the network properties, which mainly serve as the direct statistical measures of brain networks, the corresponding spatial network topologies [41] had been fully proven to facilitate our classification analysis. Therefore, based on our developed SPN method, related implicit and inherent spatial network features (i.e., SPN features) were first extracted from the resting-state EEG data from both responders and non-responders at 0 W and further utilized to classify both groups.
Here, we primarily showed the most discriminative pair of SPN filters (i.e., Filters 1 and 2), as shown in Fig. 7, in which those network nodes (e.g., electrodes O1, O2, and Oz) that exhibited significant edge differences in Fig. 6(a) displayed with larger coefficients (i.e., marked with deep red or blue color). We then used these SPN features as the discriminative features to classify responders and non-responders. Here, the LOOCV strategy was utilized to complete the categorization, and as expected, an improved performance (i.e., an accuracy of 96.67%) was indeed acquired, along with a sensitivity of 100% for responders and a specificity of 88.89% for non-responders.
Topological distribution of the most discriminative first pair of SPN filters between responders and non-responders. The subfigures in the left and right columns denote the corresponding spatial Filters 1 and 2, respectively.
D. Categorization of Merged Responders and Non-Responders From Different Sites
Considering the EMBARC recorded EEG datasets from four different sites, after testing on the participants of Columbia University, participants of the other three sites were reviewed following the same strategy used at Columbia University. Even though the EEG datasets had fewer qualified patients, both responders and non-responders could be still identified. Eventually, a total of 80 participants were picked and then included in the further categorization analysis. Just as displayed in Fig. 8, we extracted the scatter diagram of the corresponding SPN features from the first pair of filters with the most distinguishing power. From this scatter diagram, we can see that the responders and non-responder can be well distinguished; and the recognition of responders from non-responders also obtained acceptable performance, as the accuracy of 77.50% was achieved when using SPN features as the discriminative features.
Classification of responders and non-responders based on related network topologies. The scatterplot corresponding to the SPN features extracted from the first pair of the most discriminating filters between the Responders and Non-responders.
And based on these merged participants, the prediction was also achieved. Herein, by further using related network metrics to predict the efficacy after eight-week medication, as displayed in Fig. 9, the predicted HAMD17 changes were indeed correlated with diagnosed ones (
Prediction of eight-week medication efficacy for site-merged participants. The black dashed line indicates the ideal prediction, the red-solid line fits the scatter points, and the blue-filled circles denote the site-merged participants.
Discussion
The HAMD17 is the most widely used clinician-administered depression assessment scale, containing 17 items assessing depression experienced over previous weeks, which provides an indication of depression and serves as a guide to evaluate recovery. Considering the reliability and validity of HAMD17 [54], we analyzed HAMD17 scores recorded in the first two stages to illustrate the treatment efficacy after a relatively short-term medication period, as well as to explore if the HAMD17 was highly sensitive in identifying responders and non-responders. Concretely, we sought to use the efficacy of one week of medication to classify these patients with MDD. As illustrated in our present study, although these patients were divided into responders and non-responders based on their eventual HAMD17 scores recorded after eight weeks of medication, no significant difference was observed when we first explored the potential fluctuations in HAMD17 scores between 0 W and 1 W of medication. Therefore, the model failed to describe the one-week treatment efficacy and further discriminate responders and non-responders. As changes in the HAMD17 score did not show an obvious difference in distinguishing responders from non-responders, the HAMD17 scores were then directly compared between responders and non-responders at the two time points mentioned above. Unfortunately, the responders did not show a significant difference from the non-responders at either stage, as shown in Fig. 2(b). These results might be attributed to the fact that the short-term treatment was not long enough to significantly affect the brain of patients with MDD and failed to alter the HAMD17 score [55]. Clinical scales usually measure the overall performance of relatively long-term medication but not short-term results, and thus HAMD17 is not sensitive enough to detect short-term antidepressant efficacy and distinguish responders from non-responders. In this case, at the beginning of treatment, HAMD17 scores are not predictive at the individual patient level.
Considering that the human brain functions as a large-scale complex network whose information is transmitted and integrated within spatially distributed but functionally coupled regions [56], [57], potential differences in related brain networks of these responding and non-responding patients with MDD were quantitatively analyzed to objectively evaluate the therapeutic response. First, when identifying the network changes after antidepressant treatment for one week, Fig. 3 shows the significant (
Moreover, resting-state brain activity has been proven to comprise the basis of the related cognitive process [67], [68], and many studies have performed related resting-state analyses when investigating MDD dysfunction [69], [70]. In fact, the increased resting-state multiregional synchronization in patients with MDD has been proven to be accompanied by increased self-rumination, which is considered a principal cause of the psychophysiology of depression [71], [72]. Antidepressant medicines are commonly utilized to enhance monoaminergic neurotransmission and reverse some of these stress-induced neurophysiological changes, further inhibiting the abnormal activity of the amygdala, and are thus proposed to be helpful for MDD therapy [73], [74]. Here, the decreased network topologies and properties consistently clarified that one week of medication worked for responders by significantly alleviating their overall connectivity. Unfortunately, although receiving the same therapeutic intervention, the networks of those non-responding patients with MDD remained in their initial state, as no significant differences were observed between the 0 W and 1 W sessions. Here, the statistics relying on the linear mixed model did report both main effects of Group and Group-x-Time interactions for the explorations into the brain networks. The decreased network parameters consistently clarified that one week of medication worked for responders by significantly alleviating their overall connectivity. Unfortunately, although receiving the same therapeutic intervention, the networks of those non-responding patients with MDD remained in their initial state, as no significant differences were observed between the 0 W and 1 W sessions. And considering these findings, we thus assumed that the network investigation performed in our present study might be sensitive to capture the corresponding brain fluctuations occurring after one week of medication.
As resting-state networks were validated to quantitatively measure brain fluctuations after short-term treatment in patients with MDD, even within one week, the corresponding network metrics (e.g., network properties) were thus postulated to be robust biomarkers to predict therapeutic efficacy in these patients. Changes in both
Due to the significant difference between 0 W and 1 W observed in responders, whereas no difference was observed in non-responders between these two stages, we further compared and analyzed the significant differences between responders and non-responders at baseline and after one week of medication. Further analysis of the data from our current study revealed that brain networks illustrated the difference between both groups, even before antidepressant treatment. Additionally, this difference between the two groups increased significantly after one week of the therapeutic intervention. Concerning the pretreatment comparison, as displayed in the left panel of Fig. 6(a), non-responders showed enhanced network connectivity compared to responders, as mainly manifested as long-range connectivity between the temporal lobe and occipital lobe. Corresponding network properties further quantitatively revealed stronger brain activity in non-responders than in responders. As validated in previous studies [75], [76], [77], [78], non-responders experienced greater abnormal activation or overloaded communication than responders, especially within the alpha band, which might result in increased functional connectivity within the default mode network of non-responders and indeed coincided with the patterns of topological differences between responders and non-responders in Fig. 6(a). Those non-responders also received one week of antidepressant medication but failed to respond. Consequently, when further investigating the potential differences between responders and non-responders after one week of medication, increasing topological differences (i.e., much stronger and denser linkages in non-responders than responders) were observed (Fig. 6(b)), which further validated the brain fluctuations given by antidepressant treatment in responding patients with MDD by inhibiting the interaction between the frontal and temporal-occipital lobes [79]. Moreover, the difference in network properties between responders and non-responders also increased substantially after one week of medication. As observed in the two histograms, the network efficiency of non-responders remained at their initial state, while a significantly smaller
In this regard, both resting-state network properties and topologies would help distinguish responders from non-responders. Unfortunately, when both types of information were separately applied in the present classification protocols, varying performances were achieved. Although the network properties were indeed different between these responders and non-responders, both
Considering these findings described above, the network changes were indeed observed for the responders but not for the non-responders after short-term antidepressant treatment; and the differences between the two groups became even greater after one-week medication. Replicated evidence indicated that according to the HAMD17 scale, antidepressant efficacy was not observed obviously until at least 4 weeks of medication [80]. However, compared with the clinical scale, the brain network seems to be a more sensitive biomarker and has a great capacity for evaluating brain changes after short-term medication, as well as distinguishing responders from non-responders. Although the exact relationship between EEG metrics and clinical scales was still unveiled, related EEG metrics Li et al.; Zhang et al. have been proved to reliably index the deficits occurring in brain diseases, as well as evaluate the treatment response from patients. Following the similar protocol used previously [81], [82], in this study, we thus utilized brain networks to quantify the brain fluctuations after one-week medication for MDD patients, and further explored the relationship between EEG metrics and clinical scale, which aimed to provide potential early biomarkers for subsequent prediction analysis and treatment selection.
However, although we have verified our method on the EMBARC study and achieved good performance, the conclusions should be further verified, and the potential capacity for big data analysis should also be confirmed. Meanwhile, we will then develop related algorithms to mitigate the site effect induced by different amplifiers and/or electrode montages to improve the generalizability and robustness of our method.
Conclusion
Our present study investigated the differentiable resting-state networks in both responders and non-responders between 0 W and 1 W, revealing brain fluctuations after medication in patients with MDD. Although HAMD17 scores failed to evaluate the efficacy within the one week of medication therapy, the resting-state network properties succeeded and predicted the eight-week antidepressant treatment response at the individual patient level. Moreover, the baseline network topologies also distinguished medication responders from non-responders with an accuracy of 96.67%. Taken together, these findings consistently suggested that the brain network emerges as a sensitive biomarker to determine short-term treatment response and distinguish responders from non-responders, which provides a new bridge for adjusting the clinical treatment strategy.